207_Combined course Presentations

Toxicity of concurrent SRT and antibody therapy

Anti-EGF-R (cetuximab)

 Cetuximab + SRT studied only in recurrent HNC (re-RT)

 Considerable risk of severe toxicity (re-RT)

 Not clear to which extent concurrent cetuximab adds to the toxicity.

Kroeze S et al. Cancer Treatment Reviews 53 (2017) 25–37